Business, energy, technology, markets and global industry news from Business News Today

Tecentriq Hybreza

PharmaDeviceNews Tecentriq Hybreza
Hyaluronidase can temporarily loosen the hyaluronic acid-rich matrix in subcutaneous tissue, allowing large antibody doses to disperse and absorb from injection volumes that would otherwise be impractical and helping enable more convenient subcutaneous delivery of biologic medicines. Representative image.
Features & Analysis

How hyaluronidase is turning blockbuster antibody infusions into injections measured in minutes

Hyaluronidase temporarily clears a molecular barrier inside subcutaneous tissue, allowing large antibody doses to disperse and absorb from injection volumes that would otherwise be impractical.

Read More
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment

Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.

Read More
Medical Devices & Diagnostics

Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care

Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.

Read More